| Date | Title | Description |
| 09.09.2026 | Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development | Enrollment completed in cohorts evaluating invikafusp alfa monotherapy in PD-1–resistant, antigen-rich solid tumors; updated STARt-001 results selected for oral presentation at the ESMO 2026 Congress
Amy Otto appointed Senior Vice President... |
| 09.09.2026 | Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development | Enrollment completed in cohorts evaluating invikafusp alfa monotherapy in PD-1–resistant, antigen-rich solid tumors; updated STARt-001 results selected for oral presentation at the ESMO 2026 Congress
Amy Otto appointed Senior Vice President... |
| 04.08.2026 | Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion | First partnered TriSTAR program advances into IND-enabling development
Industry-leading expert in T-cell engager discovery and immune-cell activation, Saso Cemerski, joins as Senior Vice President, Head of Immunology, to accelerate expansio... |
| 04.08.2026 | Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion | First partnered TriSTAR program advances into IND-enabling development
Industry-leading expert in T-cell engager discovery and immune-cell activation, Saso Cemerski, joins as Senior Vice President, Head of Immunology, to accelerate expansio... |
| 20.07.2026 | Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory B... | Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy
Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initi... |
| 20.07.2026 | Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1–Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory B... | Updated STARt-001 results will highlight invikafusp alfa's single-agent activity in PD-1–resistant tumors using a biomarker-enrichment strategy
Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck, who led the initi... |
| 14.07.2026 | Apple Tree Partners Provides Update Following Recent Cayman Court Order | NEW YORK, July 14, 2026/PR Newswire/ -- Following the Cayman Court order issued July 10 and publicly posted on July 13, 2026, and in the context of the active and ongoing Chapter 11 restructurings of certain Apple Tree Partners (ATP) affili... |
| 14.07.2026 | Apple Tree Partners Provides Update Following Recent Cayman Court Order | NEW YORK, July 14, 2026/PR Newswire/ -- Following the Cayman Court order issued July 10 and publicly posted on July 13, 2026, and in the context of the active and ongoing Chapter 11 restructurings of certain Apple Tree Partners (ATP) affili... |
| 19.06.2026 | Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis | Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms
SAN DIEGO, June 19, 2026 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneerin... |
| 19.06.2026 | Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis | Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms
SAN DIEGO, June 19, 2026 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneerin... |
| 03.06.2026 | Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases | Combines Ascidian's RNA exon editing product engine with Lilly's leadership in genetic medicines
Programs target undisclosed inherited kidney diseases, with Lilly option to expand to additional targets
BOSTON, June 3, 2026 /PRNewswire/ -- A... |
| 03.06.2026 | Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases | Combines Ascidian's RNA exon editing product engine with Lilly's leadership in genetic medicines
Programs target undisclosed inherited kidney diseases, with Lilly option to expand to additional targets
BOSTON, June 3, 2026 /PRNewswire/ -- A... |
| 21.05.2026 | Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting | 33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy
Durable responses, Treg reduction and increased CD8/Treg ratio support i... |
| 21.05.2026 | Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting | 33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy
Durable responses, Treg reduction and increased CD8/Treg ratio support i... |
| 04.05.2026 | Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans | STELLAR to begin enrolling pediatric subjects
STARPATH prescreening study open for adults and children with Stargardt disease to streamline entry into future ACDN-01 clinical trials
BOSTON, May 4, 2026 /PRNewswire/ -- Ascidian Therapeutics,... |
| 04.05.2026 | Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans | STELLAR to begin enrolling pediatric subjects
STARPATH prescreening study open for adults and children with Stargardt disease to streamline entry into future ACDN-01 clinical trials
BOSTON, May 4, 2026 /PRNewswire/ -- Ascidian Therapeutics,... |
| 28.04.2026 | Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting | BOSTON, April 28, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster presentation at the American Socie... |
| 28.04.2026 | Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting | BOSTON, April 28, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster presentation at the American Socie... |
| 21.04.2026 | Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting | - |
| 21.04.2026 | Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--AulosTM Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Pha... |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 07.01.2026 | Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease | Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease
Collaboration secures clinical supply needed ... |
| 07.01.2026 | Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease | Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease
Collaboration secures clinical supply needed ... |
| 19.12.2025 | New Publication in Nature Communications Demonstrates the Therapeutic Utility of Targeting Synthetic Neoantigens Generated by KRAS G12C Inhibitors | Findings shared in article co-authored by Aethon Therapeutics scientists and NYU researchers support the hypothesis that combining covalent inhibitors and T cell engagers can overcome drug resistance in KRAS-mutated cancers
New York, New Yo... |
| 19.12.2025 | New Publication in Nature Communications Demonstrates the Therapeutic Utility of Targeting Synthetic Neoantigens Generated by KRAS G12C Inhibitors | Findings shared in article co-authored by Aethon Therapeutics scientists and NYU researchers support the hypothesis that combining covalent inhibitors and T cell engagers can overcome drug resistance in KRAS-mutated cancers
New York, New Yo... |
| 16.12.2025 | Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer | Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Rep... |
| 16.12.2025 | Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer | Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Rep... |
| 12.12.2025 | Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium | Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent
Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer... |
| 12.12.2025 | Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium | Safety profile of Invikafusp alfa + TRODELVY® is consistent with the known profiles of each agent
Invikafusp alfa demonstrates selective expansion of Vβ6/10 T cells when combined with TRODELVY® in previously treated metastatic breast cancer... |
| 10.12.2025 | Apple Tree Partners Initiates Voluntary U.S. Chapter 11 Cases in Delaware to Restructure Operations | NEW YORK, December 10, 2025 (PR Newswire) – Apple Tree Partners (“ATP”), a leading life sciences venture capital firm, has announced that on December 9, 2025, certain ATP affiliates filed voluntary petitions for Chapter 11 relief in the Uni... |
| 10.12.2025 | Apple Tree Partners Initiates Voluntary U.S. Chapter 11 Cases in Delaware to Restructure Operations | NEW YORK, December 10, 2025 (PR Newswire) – Apple Tree Partners (“ATP”), a leading life sciences venture capital firm, has announced that on December 9, 2025, certain ATP affiliates filed voluntary petitions for Chapter 11 relief in the Uni... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis
Replicate to provide GMP material for clinical trials and transfer ... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis
Replicate to provide GMP material for clinical trials and transfer ... |
| 07.11.2025 | New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer | Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety profile easily managed in outpatient setting; ... |
| 07.11.2025 | Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025 | 20% ORR and 80% DCR observed as monotherapy in TMB-H tumors across seven major solid tumor types, including colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), head and neck, and bladder cancers
Clinical activity was consist... |
| 07.11.2025 | New Phase 2 Data for Aulos Bioscience’s Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer | Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety profile easily managed in outpatient setting; ... |
| 07.11.2025 | Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025 | 20% ORR and 80% DCR observed as monotherapy in TMB-H tumors across seven major solid tumor types, including colorectal, lung, breast, gastric, gastroesophageal junction (GEJ), head and neck, and bladder cancers
Clinical activity was consist... |
| 17.10.2025 | Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at... | 20.5% ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, gastric, GEJ, and head and neck cancers
52% of patients experienced target-lesion tumor ... |
| 17.10.2025 | Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at... | 20.5% ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, gastric, GEJ, and head and neck cancers
52% of patients experienced target-lesion tumor ... |
| 15.10.2025 | Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 | Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and esophageal cancer
Collaboration with the Nati... |
| 15.10.2025 | Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 | Lead program from TriSTAR T cell engager platform targets Nectin-4, a clinically validated tumor antigen overexpressed across multiple solid tumors, including urothelial cancer, NSCLC, TNBC, and esophageal cancer
Collaboration with the Nati... |
| 09.10.2025 | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share
Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therap... |
| 09.10.2025 | Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share
Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therap... |
| 03.10.2025 | Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 3, 2025 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today announced the presentation of updated Phase ... |
| 03.10.2025 | Aulos Bioscience to Present Updated Phase 2 Data for Imneskibart (AU-007) in Melanoma and Non-Small Cell Lung Cancer at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif., October 3, 2025 – Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today announced the presentation of updated Phase ... |
| 24.09.2025 | Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000 | Eight month follow-up data published in Communications Medicine, a Nature portfolio journal
Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for rabies, an ongoing global public health con... |
| 24.09.2025 | Marengo to Present Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoin... | Data to be presented from the STARt-001 trial demonstrating invikafusp’s single-agent anti-tumor activity in diverse, large cancer indications
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage bio... |
| 24.09.2025 | Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000 | Eight month follow-up data published in Communications Medicine, a Nature portfolio journal
Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for rabies, an ongoing global public health con... |
| 24.09.2025 | Marengo to Present Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoin... | Data to be presented from the STARt-001 trial demonstrating invikafusp’s single-agent anti-tumor activity in diverse, large cancer indications
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage bio... |
| 22.09.2025 | Nereid Therapeutics Scientific Co-Founder Clifford Brangwynne Named a 2025 Keio Medical Science Prize Laureate | September 22, 2025/ − Clifford Brangwynne, Ph.D., co-founder of Nereid Therapeutics and professor of chemical and biological engineering at Princeton University, has been selected as a 2025 recipient of the Keio Medical Science Prize in rec... |
| 22.09.2025 | Nereid Therapeutics Scientific Co-Founder Clifford Brangwynne Named a 2025 Keio Medical Science Prize Laureate | September 22, 2025/ − Clifford Brangwynne, Ph.D., co-founder of Nereid Therapeutics and professor of chemical and biological engineering at Princeton University, has been selected as a 2025 recipient of the Keio Medical Science Prize in rec... |
| 18.09.2025 | Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-Directed ADC TRODELVY® in Metastatic Breast Cancer | Completion of Phase 1b safety run-in and determination of recommended Phase 2 dose (RP2D) enables advancement into expansion cohorts for both hormone receptor-positive, HER2-negative (HR+/HER2−) and triple-negative (mTNBC) and metastatic br... |
| 18.09.2025 | Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-Directed ADC TRODELVY® in Metastatic Breast Cancer | Completion of Phase 1b safety run-in and determination of recommended Phase 2 dose (RP2D) enables advancement into expansion cohorts for both hormone receptor-positive, HER2-negative (HR+/HER2−) and triple-negative (mTNBC) and metastatic br... |
| 03.09.2025 | Galvanize Therapeutics Raises $100 Million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease | Sofinnova Partners leads premier investor syndicate backing Galvanize's breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD.
REDWO... |
| 03.09.2025 | Galvanize Therapeutics Raises $100 Million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease | Sofinnova Partners leads premier investor syndicate backing Galvanize's breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD.
REDWO... |
| 28.08.2025 | Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes | Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases
Replicate will receive research funding and could potentially receive up to a... |
| 28.08.2025 | Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes | Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases
Replicate will receive research funding and could potentially receive up to a... |
| 31.07.2025 | Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board | Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation
Wor... |
| 31.07.2025 | Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board | Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation
Wor... |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 02.07.2025 | Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as Late-Breaking Oral Presentation at ESMO Gastrointestinal Cancer... | Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H) supported by recent FDA fast track designationNew clini... |
| 30.06.2025 | Apple Tree Partners Statement Regarding LP Litigation | Updated June 30, 2025
On May 30, 2025, Apple Tree Partners (ATP)’s fund ATP Life Science Ventures initiated litigation by filing a Complaint against its controlling limited partners (LPs) Rigmora Biotech Investor One LP and Rigmora Biotech ... |
| 30.06.2025 | Apple Tree Partners Statement Regarding LP Litigation | Updated June 30, 2025
On May 30, 2025, Apple Tree Partners (ATP)’s fund ATP Life Science Ventures initiated litigation by filing a Complaint against its controlling limited partners (LPs) Rigmora Biotech Investor One LP and Rigmora Biotech ... |
| 24.06.2025 | Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease | BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, as Chief Development Officer. The company... |
| 24.06.2025 | Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease | BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, as Chief Development Officer. The company... |
| 11.06.2025 | Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases | Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases
Deep Apple is eligible to receive up to $812 million, including an upfront payment, research c... |
| 11.06.2025 | Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases | Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases
Deep Apple is eligible to receive up to $812 million, including an upfront payment, research c... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 21.05.2025 | Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors | Appointment supports continued momentum of the company's rapidly accelerating precision oncology development strategy
CAMBRIDGE, Mass., May 21, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneeri... |
| 20.05.2025 | New Study Published on the Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection | Innovative technology offers promising non-thermal approach to soft tissue ablation without compromising sensitive structures.
REDWOOD CITY, Calif., May 20, 2025 /PRNewswire/ -- A new publication featuring Aliya® PEF has been published in t... |
| 20.05.2025 | New Study Published on the Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection | Innovative technology offers promising non-thermal approach to soft tissue ablation without compromising sensitive structures.
REDWOOD CITY, Calif., May 20, 2025 /PRNewswire/ -- A new publication featuring Aliya® PEF has been published in t... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 08.05.2025 | Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer | STARt-002 is a Phase 1b/2 clinical study assessing invikafusp alfa in combination with Gilead's Trodelvy® for HR+/HER2- and TNBC breast cancer patients across leading U.S. and Canadian breast cancer centers
CAMBRIDGE, Mass., May 8, 2025 /PR... |
| 06.05.2025 | Ascidian Therapeutics Announces Formation of Scientific Advisory Board | BOSTON, May 6, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the formation of its Scientific Advisory Board (SAB). These globally recognized leaders in ... |
| 06.05.2025 | Ascidian Therapeutics Announces Formation of Scientific Advisory Board | BOSTON, May 6, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the formation of its Scientific Advisory Board (SAB). These globally recognized leaders in ... |
| 29.04.2025 | Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting | Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors
AU-007’s unique clinical activity includes CD8 effector T c... |
| 29.04.2025 | Aulos Bioscience Presents New Phase 2 Data for AU-007 Demonstrating Continued Strong Anti-Tumor Activity in Advanced Cancers at AACR Annual Meeting | Data show clear evidence of anti-tumor activity and durable partial and complete responses in heavily pre-treated patients with tumors that progressed through checkpoint inhibitors
AU-007’s unique clinical activity includes CD8 effector T c... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 25.04.2025 | Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre... | Initial disease control rate of 67%, tumor regression rate of 44% and preliminary objective response rate of 22% were observed in TMB-H patients at the optimal biological dose range
Invikafusp alfa (STAR0602) demonstrates pan-tumor selectiv... |
| 21.04.2025 | Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025 | New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present u... |
| 21.04.2025 | Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025 | New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present u... |
| 14.04.2025 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma | LARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina... |
| 14.04.2025 | Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma | LARKSPUR, Calif., April 14, 2025 – Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of immune-activating antibody therapeutics, today announced dosing of its first patient with a combina... |
| 25.03.2025 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from the ... |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences
company discovering and developing new small-molecule therapeutics with a novel
platform to selectively modulate translation of pathogenic proteins by the r... |
| 25.03.2025 | Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 | Data to be presented from the STARt-001 trial demonstrating single agent anti-tumor activity
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for... |
| 25.03.2025 | Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic AU-007 in Melanoma at AACR Annual Meeting | - |
| 25.03.2025 | Daniel Pierce Joins Initial Therapeutics as Chief Scientific Officer | SOUTH SAN FRANCISCO, Calif., March 24, 2025 — Initial Therapeutics, a life sciences
company discovering and developing new small-molecule therapeutics with a novel
platform to selectively modulate translation of pathogenic proteins by the r... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 20.03.2025 | Marengo Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune ... | Collaboration focuses on deeper exploration of Marengo's selective dual T cell agonists in oncology, and expansion of precision T cell depleting platform across a range of autoimmune diseases
Partnership with world-renowned T cell expert E.... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 03.03.2025 | Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen | Second licensed program created with Marengo's proprietary STAR precision T cell activation platform advances to IND-enabling phase
CAMBRIDGE, Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology c... |
| 07.02.2025 | Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications | Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability
RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global pub... |
| 07.02.2025 | Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications | Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability
RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global pub... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 05.02.2025 | Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board | Barcelona-based scientific leader brings insights and experience in translational oncology research and clinical development
CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company p... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
| 10.01.2025 | Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Company presentation scheduled for Thursday, January 16, 2025 at 10AM PT follows recent clinical progress
CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel ap... |
